Current share price for FPH : $35.400 0.41 (1.17%)+
Fisher & Paykel Healthcare is a designer, manufacturer and marketer of products and systems for use in respiratory care, surgery and the treatment of obstructive sleep apnea. The company products are sold in over 120 countries.
| ASX Code | FPH |
| Website | N/A |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 20,790 |
| FPH Share Price | $35.400 |
| Day High | $35.440 |
| Day Low | $34.890 |
| Last Close | $34.990 |
| FPH Share Price Movement | $0.41 ( 1.17% ) |
As one of Australia's largest companies by market capitalisation, FPH is held across 12 ETFs spanning strategies that include health care equipment exposure . Its weighting in those funds means performance can have an outsized influence - when FPH moves, funds like FAIR, AQLT, EX20, GEAR and HVST that hold it can move with it.
For more concentrated exposure, ETFs such as FAIR (BetaShares Australian Sustainability Leaders ETF) allocate about 1.3% to FPH , while the average exposure across all 12 ETFs that hold it is around 0.4% .
Last updated: ETF data and holdings as at 3 August 2026
How does holding Fisher & Paykel Healthcare Corporation Limited (FPH) shares directly compare to ETFs that include it?
|
FPH Direct
|
FAIR
ASX |
AQLT
ASX |
EX20
ASX |
GEAR
ASX |
HVST
ASX |
|
|---|---|---|---|---|---|---|
| Holdings | 1 company | 83 holdings | 46 holdings | 193 holdings | 212 holdings | 44 holdings |
| FPH Weight | 100% | 1.3% | 1.1% | 0.6% | 0.5% | 0.5% |
| Diversification | Single Stock | Broad | Broad | Broad | Broad | Broad |
| Annual Cost | Brokerage only | 0.49% p.a. | 0.35% p.a. | 0.25% p.a. | 2.11% p.a. | 0.72% p.a. |
| Approx. Yield | 1.6% | 3.02% | 4.02% | 2.72% | 1.73% | 5.57% |
| Star Ratings | - |
Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not FPH's direct yield. Annual cost uses each ETF's MER.
How a $10,000 investment in Fisher & Paykel Healthcare Corporation Limited (FPH) one week ago compares with ETFs that hold it.
| Security | Investment type | Current price | 7-day price movement | Dollar change | Value today |
|---|---|---|---|---|---|
| Fisher & Paykel Healthcare Corporation Limited (FPH) | Direct share | $35.400 | -0.53% | -$53 | $9,947 |
| BetaShares Australian Sustainability Leaders ETF (FAIR) | Equity - Australia Strategy | $19.150 | -1.54% | -$154 | $9,846 |
| BetaShares Australian Quality ETF (AQLT) | Equity - Australia Strategy | $35.850 | -1.10% | -$110 | $9,890 |
| Betashares Australian Ex-20 Portfolio Diversifier ETF (EX20) | Equity - Australia Small/Mid Cap | $23.070 | -1.24% | -$124 | $9,876 |
| Betashares Geared Australian Equity Fund (GEAR) | Equity - Australia Strategy | $37.500 | -4.17% | -$417 | $9,583 |
| Betashares Australian Dividend Harvester Fund (HVST) | Equity - Australia Strategy | $13.430 | -1.90% | -$190 | $9,810 |
Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.
12 ETFs hold Fisher & Paykel Healthcare Corporation Limited (FPH).
| ETF | FPH Weight | MER | Yield |
|---|---|---|---|
| BetaShares Australian Sustainability Leaders ETF (FAIR) | 1.3% | 0.49% | 3.02% |
| BetaShares Australian Quality ETF (AQLT) | 1.1% | 0.35% | 4.02% |
| Betashares Australian Ex-20 Portfolio Diversifier ETF (EX20) | 0.6% | 0.25% | 2.72% |
| Betashares Geared Australian Equity Fund (GEAR) | 0.5% | 2.11% | 1.73% |
| Betashares Australian Dividend Harvester Fund (HVST) | 0.5% | 0.72% | 5.57% |
| BetaShares Australia 200 ETF (A200) | 0.2% | 0.04% | 3.21% |
| Betashares Managed Risk Australian Share Fund (AUST) | 0.2% | 0.49% | 2.98% |
| Betashares Global Cash Flow Kings ETF (CFLO) | 0.1% | 0.4% | 3.01% |
| Betashares Global Shares ETF (BGBL) | 0% | 0.08% | 1.16% |
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| HFResult | 27.01¢ | 0% | 22 Jun 2026 | 3 Jul 2026 | - | - | - |
| Result | 16.52¢ | 0% | 3 Dec 2025 | 16 Dec 2025 | - | - | - |
| HFResult | 22.26¢ | 0% | 23 Jun 2025 | 4 Jul 2025 | - | - | - |
See all dividends from Fisher & Paykel Healthcare Corporation Limited (FPH) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
| Year to Mar | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026F | $369.56 | $62.68 | 20.50% | 50.40 | 46.74 | 1.48% | 0.0% |
| 2025F | $306.71 | $52.02 | 24.40% | 60.73 | 39.37 | 1.25% | 0.0% |
| 2024A | $245.09 | $41.82 | -0.30% | 52.86 | 38.47 | 1.74% | 0.0% |
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 F | 2026 F | 2024 A | 2025 F | 2026 F | 2024 A | 2025 F | 2026 F | ||
| Cochlear Limited (COH) | $8,584M | 0.0171 | -0.1894 | 0.0615 | 21.9324 | 27.0574 | 25.4889 | 3.28% | 2.64% | 2.74% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $20,655M | 0.1388 | 0.1483 | 0.1883 | 53.1831 | 46.3129 | 38.9738 | 1.23% | 1.33% | 1.51% |
| ResMed Inc. (RMD) | $18,704M | 9.5922 | 0.0986 | 0.0885 | 20.5376 | 18.6950 | 17.1743 | 1.13% | 1.23% | 1.33% |
| Name | Position | Start Date |
|---|---|---|
| Mr Lewis George Gradon | Chief Executive Officer, Managing Director | 1 Apr 2016 |
| Sir Michael Grenfell Daniell | Non-Executive Director | 16 Nov 2001 |
| Dr Lisa Margaret McIntyre | Non-Executive Director | 1 Oct 2021 |
| Mr Andrew Mark Cross | Non-Executive Director | 1 Oct 2024 |
| Mr Graham McLean | Non-Executive Director | 1 Oct 2023 |
| Dr Cather Simpson | Non-Executive Director | 1 Jun 2022 |
| Ms Anna Curzon | Non-Executive Director | 1 Feb 2026 |
| Mr Neville Mitchell | Non-Executive Director, Non-Executive Chairman | 12 Nov 2018 |
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 17 Feb 2025 | MCLEAN, Graham | Buy | Indirect Shares | 1,000 | $32.300 | $32,300.000 |
| 12 Sep 2024 | MCLEAN, Graham | Buy | Indirect Shares | 800 | $34.915 | $27,932.000 |
| 21 Sep 2022 | O'DWYER, Donal | Buy | Indirect Shares | 3,000 | $19.261 | $57,782.000 |
See all changes in directors' interest & trades for Fisher & Paykel Healthcare Corporation Limited (FPH) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
| Name | Position |
|---|---|
| Lyndal York | Chief Financial Officer |
| Andy Niccol | Chief Operating Officer |
| Raelene Leonard | Company Secretary |
| Desh Edirisuriya | General Manager - New Zealand Operations |
| Marcus Driller | Vice President - Corporate |
| Nicola Talbot | Vice President - Human Resources |
| Nicholas Fourie | Vice President - Information & Communication Technology |
| Jonti Rhodes | Vice President - Network Design, Facilities, Infrastructure & Sustainability |
| Andrew Somervell | Vice President - Products & Technology |
| Brian Schultz | Vice President - Quality, Safety & Regulatory Affairs |
| Justin Callahan | Vice President - Sales & Marketing |
| Winston Fong | Vice President - Surgical Technologies |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Fisher & Paykel Healthcare Corporation Limited (FPH). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 44,727,643 (7.62%) | BlackRock, Inc. and related bodies corporate |
| 41,537,167 (7.07%) | Australiansuper Pty Ltd |
| Date | Event |
|---|---|
| 25 May 2027 | Report (Prelim) |
| 25 November 2026 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.